WO2005103080A3 - Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof - Google Patents
Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof Download PDFInfo
- Publication number
- WO2005103080A3 WO2005103080A3 PCT/US2005/013222 US2005013222W WO2005103080A3 WO 2005103080 A3 WO2005103080 A3 WO 2005103080A3 US 2005013222 W US2005013222 W US 2005013222W WO 2005103080 A3 WO2005103080 A3 WO 2005103080A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- oxidation resistant
- preparing same
- stable oxidation
- hemoglobin
- Prior art date
Links
- 102000001554 Hemoglobins Human genes 0.000 title abstract 4
- 108010054147 Hemoglobins Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000003647 oxidation Effects 0.000 title 1
- 238000007254 oxidation reaction Methods 0.000 title 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 abstract 2
- 239000003633 blood substitute Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Abstract
The present invention provides oxygenated hemoglobins in powdered form and methods of preparing a powdered form of a protein, such as hemoglobin, which comprise (a) mixing a solution of the protein with inulin, and optimally with a reducing sugar such as glucose or tagatose, and (b) drying the mixture. Also provided are blood substitutes formed from reconstituted powdered hemoglobins, and methods of treatment using the blood substitutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/593,387 US7678888B2 (en) | 2004-04-21 | 2005-04-20 | Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56416604P | 2004-04-21 | 2004-04-21 | |
| US60/564,166 | 2004-04-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005103080A2 WO2005103080A2 (en) | 2005-11-03 |
| WO2005103080A3 true WO2005103080A3 (en) | 2005-12-22 |
Family
ID=35197539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/013222 WO2005103080A2 (en) | 2004-04-21 | 2005-04-20 | Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US7678888B2 (en) |
| WO (1) | WO2005103080A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090140212A1 (en) * | 2006-02-24 | 2009-06-04 | Friedman Joel M | Electron Transfer Through Glassy Matrices |
| WO2007149520A2 (en) * | 2006-06-21 | 2007-12-27 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof |
| EP2543250A1 (en) | 2007-02-17 | 2013-01-09 | President and Fellows of Harvard College | Compositions and method for tissue preservation |
| EP2252281A4 (en) | 2008-02-15 | 2011-08-24 | Harvard College | Blood substitute solution |
| JP7110360B2 (en) | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | Freeze-drying method |
| WO2020185916A1 (en) | 2019-03-14 | 2020-09-17 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3964865A (en) * | 1975-01-30 | 1976-06-22 | Sigma Chemical Company | Lyophilized human hemoglobin standard for colorimetric determination of total hemoglobin |
| US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5716815A (en) * | 1980-07-02 | 1982-01-28 | Ajinomoto Co Inc | Oxygen transporting agent for artificial blood |
| US4425334A (en) * | 1982-04-02 | 1984-01-10 | The Regents Of The University Of California | Functional oxygen transport system |
| FR2600894B1 (en) * | 1986-07-02 | 1989-01-13 | Centre Nat Rech Scient | MACROMOLECULAR CONJUGATES OF HEMOGLOBIN, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS |
| FR2630329B1 (en) * | 1988-04-20 | 1991-07-05 | Merieux Inst | MACROMOLECULAR CONJUGATES OF HEMOGLOBIN, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS |
| WO1994018954A1 (en) * | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US6747132B2 (en) * | 2000-11-29 | 2004-06-08 | Apex Biosciences, Inc. | Methods for the synthesis of a modified hemoglobin solution |
| WO2003045163A1 (en) * | 2001-11-27 | 2003-06-05 | Auckland Uniservices Limited | Sugar-protein conjugates and their formation |
| US20090140212A1 (en) | 2006-02-24 | 2009-06-04 | Friedman Joel M | Electron Transfer Through Glassy Matrices |
| WO2007149520A2 (en) | 2006-06-21 | 2007-12-27 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof |
-
2005
- 2005-04-20 US US10/593,387 patent/US7678888B2/en not_active Expired - Fee Related
- 2005-04-20 WO PCT/US2005/013222 patent/WO2005103080A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3964865A (en) * | 1975-01-30 | 1976-06-22 | Sigma Chemical Company | Lyophilized human hemoglobin standard for colorimetric determination of total hemoglobin |
| US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
Non-Patent Citations (1)
| Title |
|---|
| HELLER ET AL.: "Conformational Stability of Lyophilized EGylated Proteins in an Phase Separating System.", JOURNAL OF PHARMACEUTICAL SCIENCES., vol. 88, no. 1, January 1999 (1999-01-01), pages 58 - 64, XP002988585 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005103080A2 (en) | 2005-11-03 |
| US20080039370A1 (en) | 2008-02-14 |
| US7678888B2 (en) | 2010-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005103080A3 (en) | Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof | |
| ATE551362T1 (en) | PEPTIDES THAT LOWER BLOOD SUGAR CONTENT | |
| WO2005089483A3 (en) | Low glycemic sweeteners and products made using the same | |
| WO2007064618A8 (en) | Methods for the treatment of muscle loss | |
| WO2007128817A3 (en) | Insulin derivative | |
| WO2005082927A3 (en) | Antihypertensive peptides | |
| WO2006071342A3 (en) | Cardiovascular compositions | |
| WO2007024700A3 (en) | Exendin for treating diabetes and reducing body weight | |
| WO2006096774A3 (en) | Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers | |
| MY158890A (en) | Pegylated insulin lispro compounds | |
| WO2007041365A3 (en) | 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | |
| WO2007044693A3 (en) | Multi-functional ionic liquid compositions | |
| IL186772A0 (en) | Glp-1 pegylated compounds | |
| WO2007070504A3 (en) | Stable and palatable oral liquid sumatriptan compositions | |
| WO2008135960A3 (en) | A composition for increasing stamina | |
| WO2004103285A3 (en) | Lactoferrin in the treatment of diabetes mellitus | |
| WO2009116894A3 (en) | Oxygen-transferring blood substitute and a pharmaceutical composition (variants) | |
| WO2004024167A3 (en) | Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes | |
| WO2008136888A3 (en) | Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders | |
| WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes | |
| WO2004069194A3 (en) | Use of the oxidoreductase ncb50r for diagnosings and treating diabetes | |
| WO2007097922A3 (en) | Receptor-based blood detoxification system | |
| WO2010005961A3 (en) | Nutritive compositions and methods of using same | |
| WO2005041898A3 (en) | Blood substitutes | |
| WO2006031993A3 (en) | Enhancing recombinant hemoglobin production by co-expression with alpha hemoglobin stabilizing protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 10593387 Country of ref document: US |